LDN-214117 is a potent and selective small molecule inhibitor of the BMP type I receptor ALK2, which disrupts bone morphogenetic protein (BMP) signaling pathways. It is primarily utilized in biomedical research to study the effects of BMP inhibition on cellular processes such as differentiation, proliferation, and fibrosis. This compound has been employed in preclinical models to explore its potential in conditions like heterotopic ossification, pulmonary fibrosis, and stem cell biology, contributing to insights into developmental biology and disease mechanisms. While promising for advancing therapeutic strategies, LDN-214117 remains a research tool and is not approved for clinical or industrial applications.